Literature DB >> 27736284

Continuous Perioperative Sublingual Buprenorphine.

Marcelina Jasmine Silva, Andrea Rubinstein.   

Abstract

Buprenorphine, a semisynthetic thebaine derivative, is a unique opioid, as it has activity at multiple receptors, including mu (partial agonist), kappa (antagonist), OLR-1 (agonist), and delta (antagonist). Because buprenorphine's pharmacology is relatively complex, misconceptions about its actions are common. Most other opioids act solely or predominately as full mu receptor agonists. Common practice at many institutions calls for the cessation of regular buprenorphine use 48-72 hours prior to surgery. This practice is based on three foundational theories that have come from scant data about the properties of buprenorphine: (1) that buprenorphine is only a partial mu agonist and therefore is not a potent analgesic; (2) because buprenorphine has a ceiling effect on respiratory depression, it also has a ceiling effect on analgesia; and (3) that buprenorphine acts as a "blockade" to the analgesic effects of other opiates when coadministered due to its strong binding affinity. However, several recent studies have called this practice into question. At our institution, we continue buprenorphine perioperatively, whenever possible, in order to provide superior pain control, discourage potentially problematic use and the more dangerous side effects of full mu agonist opiates, and avoid putting recovery at risk for those with opiate dependency issues. We present a unique case comparing two different outcomes for the same surgical course performed at two different times on the same chronic pain patient. These differences may be attributable to the variable of buprenorphine being present for one perioperative course and not the other. Pain control was easier to achieve, and functional recovery was greater when buprenorphine was maintained throughout the perioperative period when compared with using a full mu agonist opioid for chronic pain preoperatively. This is an outcome that much of the literature heretofore suggests would be unlikely. We review some aspects of buprenorphine's unique pharmacology that may explain why remaining on buprenorphine perioperatively may be preferable, which contradicts many practice guidelines.

Entities:  

Keywords:  acute pain control in chronic pain patients; buprenorphine; opioid dependence; opioid maintenance therapy; perioperative pain control

Mesh:

Substances:

Year:  2016        PMID: 27736284     DOI: 10.1080/15360288.2016.1231734

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  6 in total

Review 1.  Treating Perioperative and Acute Pain in Patients on Buprenorphine: Narrative Literature Review and Practice Recommendations.

Authors:  Megan Buresh; Jessica Ratner; Aleksandra Zgierska; Vitaly Gordin; Anika Alvanzo
Journal:  J Gen Intern Med       Date:  2020-08-21       Impact factor: 5.128

2.  The effect of preoperative sublingual buprenorphine on postoperative pain after lumbar discectomy: A randomized controlled trial.

Authors:  Farshad Hassanzadeh Kiabi; Seyed Abdollah Emadi; Misagh Shafizad; Abdolmajid Gholinataj Jelodar; Hojat Deylami
Journal:  Ann Med Surg (Lond)       Date:  2021-05-01

3.  Perioperative Pain and Addiction Interdisciplinary Network (PAIN): protocol of a practice advisory for the perioperative management of buprenorphine using a modified Delphi process.

Authors:  Saam Azargive; Joel S Weissman; Akash Goel; Harsha Shanthanna; Karim S Ladha; Wiplove Lamba; Scott Duggan; John G Hanlon; Tania Di Renna; Philip Peng; Hance Clarke
Journal:  BMJ Open       Date:  2019-05-22       Impact factor: 2.692

Review 4.  Perioperative Management of Patients on Buprenorphine and Methadone: A Narrative Review

Authors:  Yasmin Sritapan; Sean Clifford; Alexander Bautista
Journal:  Balkan Med J       Date:  2020-05-14       Impact factor: 2.021

5.  The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes.

Authors:  Akash Goel; Saam Azargive; Wiplove Lamba; Joel Bordman; Marina Englesakis; Sanjho Srikandarajah; Karim Ladha; Tania Di Renna; Harsha Shanthanna; Scott Duggan; Philip Peng; John Hanlon; Hance Clarke
Journal:  Can J Anaesth       Date:  2018-11-27       Impact factor: 5.063

6.  Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.

Authors:  Anna Lembke; Einar Ottestad; Cliff Schmiesing
Journal:  Pain Med       Date:  2019-03-01       Impact factor: 3.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.